BCMA-Targeted Therapy in RRMM: Management of Adverse Events

Prevention and Management of Bispecific Antibody Associated Adverse Events in Multiple MyelomaПодробнее

Symposium | Practical management of adverse events with immunotherapiesПодробнее

BCMA-Targeted Therapy in RRMM: Results From the DREAMM-1 TrialПодробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее

Treating multiple myeloma resistant to BCMA-targeted therapyПодробнее

RedirecTT-1 Study: Dual Targeting of BCMA and GPRC5D in RRMM Pts with Teclistamab and TalquetamabПодробнее

BCMA-Targeted Therapy in RRMM: Future Challenges and BiTEПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Symposium | How to sequence BCMA-directed therapies in RRMMПодробнее

Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted AgentsПодробнее

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024Подробнее

BCMA Antibodies and Cellular Therapies in RRMMПодробнее

What’s Next for BCMA-Targeted ADCs and CAR-T Therapy in RRMM?Подробнее

Managing progression after BCMA-targeted therapy in R/R multiple myelomaПодробнее

Sequencing BCMA Myeloma TherapiesПодробнее

BCMA-Targeted Therapies in Multiple MyelomaПодробнее

ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa resultsПодробнее

Using BCMA-targeting agents in earlier lines of treatment for multiple myelomaПодробнее

Outcomes of teclistamab in RRMM with prior exposure to BCMA-directed therapyПодробнее